UZCHS CTU

乌兹别克斯坦CTU

• 批准号: 9180667
• 负责人: ZVAVAHERA MIKE CHIRENJE
• 金额: $ 321.03万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2020-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9180667
• 关键词: AIDS clinical trial group; AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Adult; Area; California; Caring; Centers of Research Excellence; Child; Childhood; Clinical; Clinical Trials; Clinical Trials Unit; Collaborations; Communities; Comorbidity; Complement; Data; Enrollment; Environment; Epidemiology; Funding; Future; Geographic Locations; Grant; HIV; HIV Infections; HIV therapy; Health Sciences; Hepatitis; Human Resources; IMPAACT; Incidence; Infection; Institution; International; Laboratories; Leadership; Mission; National Institute of Allergy and Infectious Disease; Pathogenesis; Persons; Pharmacy facility; Policies; Policy Maker; Population; Populations at Risk; Positioning Attribute; Prevalence; Prevention; Prevention Research; Prevention strategy; Protocols documentation; Research; Research Personnel; San Francisco; Science; Site; Structure; Therapeutic; Therapeutic Human Experimentation; Training; Translating; Tuberculosis; United States National Institutes of Health; Universities; Vertical Disease Transmission; Zimbabwe; authority; clinical research site; clinically relevant; college; evidence base; experience; flexibility; microbicide; outreach; prevent; programs; screening

DESCRIPTION (provided by applicant): The University of Zimbabwe-University of California, San Francisco Collaborative Research Programme (UZUCSF), in collaboration with the University of California, San Francisco (UCSF), is the site of a well-established, large Clinical Trials Unit (CTU) with 4 Clinical Research Sites (CRSs), covering 6 distinct geographic locations within and surrounding Harare, Zimbabwe. Experience gained from leadership and participation in 4 Division of AIDS (DAIDS) Networks (HPTN, MTN, ACTG, IMPAACT), positions the CTU to continue its contribution to the global understanding of HIV epidemiology and pathogenesis by serving as a center of research excellence in the prevention and control of HIV and AIDS. Utilizing the expertise of our international and local complement of investigators and highly trained and experienced research personnel, the CTU will accomplish this through completion of the following Specific Aims: 1.a. Identifying, screening, enrolling, and retaining existing and new at-risk populations in an environment of declining prevalence and incidence, in the following mission-specific domains of scientific priority of the 4 future NIAID-sponsored Networks: i) Adult HIV Therapeutic Strategies, including HIV cure, noninfectious comorbidities, and the infectious co-morbidities of hepatitis and tuberculosis; ii) Strategies to Address HIV and HIV-associated Infections in Pediatric and Maternal Populations; iii) Integrated HIV Prevention Strategies; and iv) Microbicide Strategies to Prevent HIV infections, and 1.b. Contributing to the scientific leadership of the 4 future NIAID-sponsored Networks. 2. Utilizing an increasingly efficient and sophisticated centralized administrative structure to support the uninterrupted execution of protocols across 4 restructured CRSs, laboratory, and pharmacy components. 3. Leveraging the integral relationships developed with the CTU's community partners and diverse stakeholders to disseminate research findings and translate research results into evidence-based best practices and policies at the local, regional, and international levels. RELEVANCE: The CTU's implementation of protocols across the 4 Networks may produce results that translate to policies within Zimbabwe and internationally to reduce HIV incidence and prevalence. The CTU anticipates that this new evidence will further inform policies to reduce the Zimbabwean HIV incidence from its current 3% to 2%; reduce current HIV prevalence from 13% to 7.5%; reduce HIV vertical transmission from the current 14% to <5%; and reduce TB incidence from 633 per 100,000 persons to 200 per 100,000.

描述（由申请人提供）：津巴布韦大学-加州大学旧金山分校合作研究项目 (UZUCSF) 与加州大学旧金山分校 (UCSF) 合作，是一个完善的大型临床研究项目的所在地。试验单位 (CTU) 拥有 4 个临床研究中心 (CRS)，覆盖津巴布韦哈拉雷及其周边地区的 6 个不同地理位置。通过领导和参与艾滋病毒 (DAIDS) 网络 4 个部门（HPTN、MTN、ACTG、IMPAACT）获得的经验，使 CTU 能够作为艾滋病毒流行病学和发病机制的卓越研究中心，继续为全球艾滋病毒流行病学和发病机制的理解做出贡献。预防和控制艾滋病毒和艾滋病。利用我们国际和当地研究人员以及训练有素且经验丰富的研究人员的专业知识，CTU 将通过完成以下具体目标来实现这一目标： 1.a.识别、筛选、注册和保留现有的和新的 在流行率和发病率下降的环境中，在以下 4 个未来 NIAID 赞助网络的科学优先任务特定领域中，针对高危人群： i) 成人艾滋病毒治疗策略，包括艾滋病毒治疗、非传染性合并症、 以及肝炎和结核病的传染性合并症； ii) 应对艾滋病毒的策略和 儿科和孕产妇中与艾滋病毒相关的感染； iii) 艾滋病毒综合预防策略； iv) 预防 HIV 感染的杀微生物剂策略，以及 1.b。为 NIAID 赞助的 4 个未来网络的科学领导力做出贡献。 2. 利用日益高效和复杂的集中管理结构，支持 4 个重组后的 CRS、实验室和药房组件不间断地执行方案。 3. 利用与 CTU 社区合作伙伴和不同利益相关者建立的整体关系，传播研究成果，并将研究成果转化为地方、区域和国际层面循证最佳实践和政策。 相关性：CTU 在 4 个网络中实施协议可能会产生成果，转化为津巴布韦国内和国际上减少艾滋病毒发病率和流行率的政策。 CTU 预计这一新证据将进一步为将津巴布韦艾滋病毒发病率从目前的 3% 降低至 2% 的政策提供依据；将目前的艾滋病毒感染率从 13% 降低至 7.5%；将艾滋病毒垂直传播从目前的 14% 降低至 <5%；将结核病发病率从每 10 万人 633 例降低到每 10 万人 200 例。